Before 2022, businesses could deduct research and development expenses immediately under IRC Section 174. Starting with the 2022 tax year, the Tax Cuts and Jobs Act eliminated immediate expensing and required companies to amortize domestic R&D expenses over five years (15 years for foreign R&D). This change significantly affects cash flow for R&D-intensive businesses.
What Changed
Under the old rules, a company spending $1M on qualifying Section 174 expenses could deduct the full $1M in the year spent. Under the new rules, that same $1M must be deducted over five years using the mid-year convention—meaning $100,000 in year one, $200,000 in years two through five, and $100,000 in year six. The total deduction is the same; the timing is radically different.
The Impact on R&D-Intensive Companies
For software companies, pharmaceutical developers, and other R&D-heavy businesses, the Section 174 change creates a significant cash flow impact. The effective tax liability in the first year of a major R&D investment may be substantially higher than pre-2022. This makes the R&D tax credit—which provides a dollar-for-dollar reduction in tax liability—more valuable than ever as a partial offset.
Key Takeaways
- Section 174 now requires 5-year amortization of domestic R&D costs, not immediate expensing.
- The R&D tax credit (Section 41) is unchanged and partially offsets the Section 174 cash flow impact.
- Consult a tax professional to model the impact on your specific situation and explore whether the payroll tax credit offset applies.
